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Background: Glibenclamide (Gli) binds to the sulphonylurea receptor (SUR) that is a regulatory subunit of
ATP-sensitive potassium channels (KATP channels). Binding of Gli to SUR produces the closure of KATP channels and
the inhibition of their activity. This drug is widely used for treatment of type 2-diabetes and it has been signaled as
antiproliferative in several tumor cell lines. In previous experiments we demonstrated the antitumoral effect of Gli in
mammary tumors induced in rats. The aim of the present work was to investigate the effect of Gli on MDA-MB-231
breast cancer cell proliferation and to examine the possible pathways involved in this action.
Results: The mRNA expression of the different subunits that compose the KATP channels was evaluated in
MDA-MB-231 cells by reverse transcriptase-polymerase chain reaction. Results showed the expression of mRNA for
both pore-forming isoforms Kir6.1 and Kir6.2 and for the regulatory isoform SUR2B in this cell line. Gli inhibited cell
proliferation assessed by a clonogenic method in a dose dependent manner, with an increment in the population
doubling time. The KATP channel opener minoxidil increased clonogenic proliferation, effect that was counteracted
by Gli. When cell cycle analysis was performed by flow cytometry, Gli induced a significant cell-cycle arrest in G0/G1
phase, together with an up-regulation of p27 levels and a diminution in cyclin E expression, both evaluated by
immunoblot. However, neither differentiation evaluated by neutral lipid accumulation nor apoptosis assessed by
different methodologies were detected. The cytostatic, non toxic effect on cell proliferation was confirmed by
removal of the drug.
Combination treatment of Gli with tamoxifen or doxorubicin showed an increment in the antiproliferative effect
only for doxorubicin.
Conclusions: Our data clearly demonstrated a cytostatic effect of Gli in MDA-MB-231 cells that may be mediated
through KATP channels, associated to the inhibition of the G1-S phase progression. In addition, an interesting
observation about the effect of the combination of Gli with doxorubicin leads to future research for a potential
novel role for Gli as an adjuvant in breast cancer treatment
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Sulphonylureas are used to increase insulin secretion in
patient with type 2-diabetes due to their direct action on
pancreatic β cells. These drugs bind to the β cell sulpho-
nylurea receptor (SUR) that is a regulatory subunit of
ATP-sensitive potassium channels (KATP channels) [1-3].
KATP channels regulate the transport of potassium ions
through cell membranes. A diverse group of compounds
can bind to KATP channels causing them to open or
close. The opening of potassium channels in the cell
membrane produces a hyperpolarization of membrane
potential. These channels are hetero-octameric com-
plexes that consist of two rings: an inner ring of four in-
wardly rectifying K+ channels (Kir6.X) that forms the
pore through which potassium ions pass, and an outer
ring that comprises four SUR subunits. Two isoforms
have been described for Kir6.X (Kir6.1 and Kir6.2) and
also for SUR (SUR1 and SUR2; SUR2 also has two splice
variants, SUR2A and SUR2B) [4]. In pancreatic β cells
binding of sulphonylureas to SURs produce the closure
of KATP channels reducing cellular potassium efflux thus
favoring membrane depolarization, the induction of Ca2+
influx, and insulin secretion [1-3].
Glibenclamide (Gli), a diarylsulphonilurea that blocks
specifically KATP channels, is widely employed in the
treatment of diabetic patients [5], but various reports
also described its antiproliferative effect in different neo-
plastic cell lines [6,7]. Additionally, the inhibition of
other classes of potassium channels also leads to a de-
crease of proliferation in normal and cancer cells [8,9].
Breast cancer is the neoplastic disease most frequently
observed in women all over the world [10-12]. A high
proportion of mammary tumors are positive for estrogen
receptors α (ERα) and consequently antihormonal ther-
apy is indicated. The selective estrogen receptor modula-
tor tamoxifen continues to be the drug regularly used in
patients harboring this kind of tumors due to its efficacy
and low toxicity [13]. However, approximately 30% of
ERα (+) tumors do not respond to tamoxifen or develop
resistance in the course of the treatment. In addition, it
is known that approximately 30% of tumors do not ex-
press ERα [14]. Although a large number of drugs have
been developed for the treatment of ERα (−) tumors,
most of them give rise to important toxic effects. In
order to attain better therapeutic effectiveness, combin-
ation cytotoxic treatments for aggressive cancers have
been employed in clinics. The simultaneous use of drugs
with different molecular targets can delay the emergence
of chemoresistance whereas when drugs are directed to
the same cellular pathway they could work synergically
for higher efficacy and selectivity. However, combination
therapy may also increase toxicity [15]. Doxorubicin is
considered a highly effective agent in the treatment of
aggressive breast cancer patients sometimes combinedwith cyclophosphamide, taxanes and/or 5-fluorouracil;
however, resistance to doxorubicin is common [16,17].
The search for effective drugs with low side effects is
still a challenge to researchers.
MDA-MB-231 cell line derived from a human breast car-
cinoma that do not express ERα, is often used as an experi-
mental non hormone-dependent tumor model [18,19].
The objective of the present work was to investigate the ef-
fect of Gli on MDA-MB-231 cells proliferation and to
examine the possible pathways involved in this action.
Material and methods
Materials
MBA-MB-231 cells were obtained from American
Type Culture Collection (ATCC). Gli was kindly pro-
vided by Investi-Farma SA, Buenos Aires, Argentina.
Tamoxifen (Tam) was a gift from Gador Laboratories
SA, Buenos Aires, Argentina. RPMI 1640 medium
and fetal bovine serum (FBS) were purchased from
GIBCO, Invitrogen, CA, USA. Ribonuclease, propidium
iodine, 3,30dihexyloxacarbocyanine iodide (DiOC6),
saponine, FITC-labeled anti-rabbit, 5-bromo-20-deoxyuri-
dine (BrdU), mouse anti-BrdU monoclonal antibody,
FITC-conjugated anti-mouse IgG, 40,6-Diamidino-2-
phenyindole, dilactate (DAPI), 5-bromo-4-chloro-3-indo-
lyl-β-d-galactoside (X-gal), mouse anti-β-actin polyclonal
antibody, p27Kip1 monoclonal antibody and Nile-red stain
were purchased from Sigma, St Louis, MO, USA. Apop-
tagWPLUS Peroxidase In Situ Detection Kit S701 was from
Chemicon International, CA, USA. Rabbit polyclonal anti-
bodies against human Bax, Bcl-2 and Bcl-xL/S were from
Santa Cruz Biotechnologies, Santa Cruz, CA, USA. Mouse
anti-cyclin B1 monoclonal antibodies, mouse anti-cyclin E
monoclonal antibodies, and rabbit anti-cyclin D1 monoclo-
nal antibodies were from Cell Signaling Technology, Inc.,
Danvers, MA, USA. Annexin V-FITC was from Bios-
ciences, USA. Chemiluminiscence system (ECL) was from
Amersham Biosciences Argentina SS (Argentina). Nitrocel-
lulose membranes were from Santa Cruz Biotechnologies,
Santa Cruz, CA, USA. Multiwells were from TPP, Switzer-
land. All other reagents were of analytical grade.
Methods
Reverse transcriptase polymerase chain reaction (RT-PCR)
analysis
Total cellular RNA was extracted using TrizolW accord-
ing to the instructions of the manufacturer (GIBCO, Life
Technologies, USA). Total RNA (2 μg) was added to the
reverse transcription (RT) reaction mixture (20 μl) in
the presence of oligo-dT primers and samples were
incubated at 37°C for 60 minutes. The quality of each
individual’s cDNA was confirmed by PCR with primers
for β-actin producing bands of the expected size (data
not shown).The primers used were employed previously
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and SUR2B [20]. PCR conditions were as follows: Kir6.1
forward (5′-CATCTTTACCATGTCCTTCC-3′) and re-
verse (5′-GTGAGCCTGAGCTGTTTTCA-3′), 336 bp;
Kir6.2 forward (5′-GCTTTGTGTCCAAGAAAGG1-3′)
and reverse (5′-CCAAAGCCAATAGTCACTTG-3′),
301 bp; 5 min 95°C, 35 cycles of 95°C for 20 s, 52°C for
45 s, and 72°C for 1 min. SUR1 forward (5′-CGATGC
CATCATCACAGAAG-3′) and reverse (5′-CTGAG
CAGCTTCTCTGGCTT-3′), 291 bp; SUR2A foward
(5′-ATGCGGTTGTCACTGAAGG-3′) and reverse (5′-
AATAGAAGAGACACGGTGAGC-3′), 215 bp; SUR2B
forward (5′-GATGCGGTTGTCACTGAAGG-3′) and re-
verse (5′-TCATCACAATAACCAGGTCTGC-3′), 244 bp;
5 min 95°C, 35 cycles of 95°C for 1 min, 55°C for 1 min,
and 72°C for 2 min. Reactions were terminated by final
elongation step of 7 min at 72°C (Gene Amp PCR System
2400, PerkinElmer, MA, USA). Negative controls were per-
formed with water instead of cDNA. PCR products were
subjected to gel electrophoresis and detected by gel docu-
mentation system LumiBis DNR (Bio-Imaging Systems,
Jerusalem, Israel).
Cell culture
MBA-MB-231 cels were cultured in RPMI 1640 medium
supplemented with 10% FBS, 0.3 g/l L-glutamine and
40 mg/l gentamicine and in the presence of Gli, Tam or
vehicle. Cells were maintained at 37°C in a humidified
atmosphere containing 5% CO2.
Cell proliferation assay
For clonogenic assay, cells were seeded in 6-well plates
(1.5×103 cells/well) and incubated in the presence or ab-
sence of drugs for 10 days. Cells were treated with 10 to
50 μM Gli, 0.005 to 5 μM minoxidil; 0.1 to 5 μM tam-
oxifen; 0.01 to 0.1 nM doxorubicin or with the concen-
tration of Gli that inhibited the proliferation to the 50%
(IC50) plus different doses of minoxidil, tamoxifen or
doxorubicin to assess the combined action of both
drugs. Cells were then fixed with 10% formaldehyde in
phosphate-buffered saline, PBS, stained with 1% tolui-
dine blue in 70% ethanol. The clonogenic proliferation
was evaluated by counting the colonies with 50 cells or
more. The results are expressed as a percentage of con-
trol values.
Determination of doubling time
For doubling time determination cells were seeded in
6-well plates (4×104 cells/well), starved for 24 h and
then incubated with IC50 Gli (25 μM) or vehicle for
up to 96 h. Cells were trypsinized at 0, 1, 2, 3 and
4 days and counted using a hemocytometer. All
experiments were performed in the logarithmic phase
of cell growth. Triplicate plates were analyzed for eachtreatment and each time. The following formula was
used to calculate the doubling time: Nt = N0 x e
kxt, where
N0 was the initial number of cells that increased expo-
nentially with a rate constant, k. The doubling time (T)
was calculated as: T = ln 2/k. The GraphPad Prism 5.0
software (GraphPad Software Inc., Philadelphia, U.S.A.)
was employed.
Cell cycle analysis by flow cytometry
Cells were cultured for 24 h without FBS. Synchro-
nized cells were then treated with IC50 Gli (25 μM) or
vehicle immediately after release from the block and
harvested for up to 72 h. Then cells were collected by
trypsinization, fixed with ice cold methanol, centri-
fuged and resuspended in 0.5 ml of propidium iodide
(PI) staining solution (50 μg/ml PI in PBS containing
0.2 mg/ml of DNase-free RNase A). After incubation
for 30 min at 37°C, samples were evaluated by flow
cytometry (Becton Dickinson, USA). Cell cycle distri-
bution was analyzed using Cylchred 1.0.2 software
(Cardiff University, UK).
Quantification of DNA synthesis
The quantification of cellular DNA synthesis was per-
formed on cells by the addition of 30 μM BrdU for 2 h.
Cells grown on sterile slides were washed with PBS and
fixed with 10% formaldehyde in PBS. To denature the
DNA into single-stranded molecules, cells were incu-
bated with 3 N HCl for 30 min at room temperature.
Then cells were washed in 1 ml of 0.1 M Na2B4O7,
pH 8.5 to neutralize the acid and were then incubated
overnight at 4°C with mouse anti-BrdU monoclonal anti-
body (1:50). Then, cells were incubated for 2 h at 37°C with
FITC-conjugated anti-mouse IgG (1:100). After washed
with PBS, cells were stained with DAPI (1:8000). Fluores-
cence was further visualized by fluorescence microscope.
At least 1000 cells were scored for each determination.
Apoptosis
Apoptotic MDA-MB-231 cells were detected after treat-
ment with Gli or vehicle for 72 h. Phosphatidylserine ex-
posure on the surface of apoptotic cells was detected by
flow cytometry after staining with Annexin V-FITC and
PI (50 μg/ml). Data were analyzed using WinMDI 2.8
software (Scripps Institute, CA, USA).
Mitochondrial transmembrane potential
Variations of the mitochondrial transmembrane poten-
tial of the cells, ΔΨm, were studied by means of the up-
take of DiOC6, a specific fluorochrome that has been
widely used in monitoring ΔΨm. Cells were plated and
treated 24 h after with 25 μM Gli for different incuba-
tion periods (24, 48 and 72 hs). The diluted dye at a final
concentration of 40 nM in PBS was applied to cells for
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harvested and then analyzed by flow cytometry (Becton
Dickinson, USA). Results were expressed as the percent-
age of mean fluorescence of respective controls.
Determination of cell cycle and apoptosis related proteins
Flow cytometry
After treatment with Gli or vehicle for 72 h MDA-MB-
231 cells were harvested, fixed with 4% formaldehyde
and permeabilized with saponine. To evaluate intracellu-
lar protein content, cells were incubated with rabbit
anti-Bcl-2 and rabbit anti-Bax antibodies. After washing,
cells were incubated for 20 min with FITC-labeled anti-
rabbit. The samples were analyzed with a FACScalibur
flow cytometer (Becton Dickinson, USA). Data analysis
was performed using WinMDI 2.8 software. For each
sample 20,000 events were collected. The results are
expressed as the percentage of respective control values.
Western blot assay
Cells were placed on ice and washed twice with cold
PBS. Cells were then scraped into a lysis buffer (100 mM
Tris/HCl buffer, pH 8, containing 1% Triton X-100 and
protease inhibitors) and incubated for 15 min on ice.
After centrifugation at 6000 rpm for 10 min, the super-
natants were used for protein determination according
to Bradford assay [21]. For Western blot, loading buffer
(100 mM Tris/HCl buffer, pH 8, containing 1.7% sodium
dodecyl sulfate (SDS), 0.02% bromophenol blue, 1.5%
dithiotreitol, and 5% of glycerol) was added to samples
and they were boiled for 3 minutes. Equal amounts of pro-
teins (50 μg) were fractionated on SDS-polyacrylamide gels
(12%) and transferred electrophoretically onto nitrocellu-
lose membranes. Membranes were blocked and probed
overnight with primary mouse anti-cyclin D1 (1:100),
mouse anti-cyclin E (1:500), mouse anti-cyclin B (1:200),
mouse anti-p27Kip1 (1:200), rabbit anti-Bax (1:500), rabbit
anti-Bcl-xL/S (1:500) and mouse anti-β-actin (1:1000) anti-
bodies. Immunoreactivity was detected by using horserad-
ish peroxidase-conjugated anti-mouse or anti-rabbit IgG,
as appropriate, and visualized by enhanced chemilumines-
cence. Densitometric analyses were performed using the
software Image J 1.32 J (NIH, USA).
Evaluation of senescence-like phenotype
Senescence-associated β-galactosidase (SA-β-Gal) activ-
ity was detected in cells as previously described by Dimri
[22] with some modifications. Cells treated with Gli
(25 μM) or vehicle for 72 hs were fixed in 3.0% formal-
dehyde for 5 min, washed in phosphate buffered solution
(PBS) and stained in 1 mg/ml X-gal solution at pH 6.0
for 4 hs at 37°C. SA-β-Gal positive cells were stained in
blue. To visualize the cell architecture, the slides were
counter-stained by haematoxylin and quantified byoptical microscopy. At least 1000 cells were scored for
each determination.
Lipid accumulation
In order to examine the possible action of Gli in lipid ac-
cumulation, a classic terminal differentiation marker in
mammary cells, the levels of neutral lipid were measured
by flow cytometry using Nile-red staining [23]. Cells
treated with Gli or vehicle for 2, 3 or 7 days were fixed
and then incubated with Nile-red at a final concentra-
tion of 1 μg/ml in PBS for 20 min at room temperature.
Cells were then analyzed by flow cytometry (Becton
Dickinson, USA).
Data analysis was performed using WinMDI 2.8 soft-
ware (Scripps Institute, CA, USA). The results were
expressed as a percentage of control values.
Cytostatic effect of glibenclamide
MDA-MB-231 cells (1x104 cells/well) were plated into
6-well plates. After 24 h, cells were treated with 25 μM
Gli or vehicle and detached with trypsin 3 or 7 days
later. Cells were then counted and seeded in 6-well
plates (1.2×103 cells/well) in triplicates. After 10 days in
culture, colonies were fixed with 10% buffered formalin
and stained with 1% toluidine blue in 70% ethanol. The
number of colonies was determined and normalized to
the number of colonies in controls.
Statistical analysis
In all cases the data shown are the means ± SEM of at
least three independent experiments. Statistical analysis
is indicated in each legend. Data were analyzed using the
GraphPad Prism 5.0 (GraphPad Software Inc., Philadelphia,
U.S.A.) and P values less than 0.05 were considered statisti-
cally significant.
Results
Expression of KATP channels in MDA-MB-231 cells
Though many reports describe the presence of different
potassium channels in diverse human cancer cell lines,
at present there is little evidence about the expression of
KATP channels in breast cancer cells. Since Gli is a spe-
cific blocker of KATP channels, the expression of mRNA
for different subunits (Kir6.1, Kir6.2 and SURs) was
examined by RT-PCR in MDA-MB-231 cells. As shown
in Figure 1A bands of 336 and 301 bp for Kir6.1 and
Kir6.2 respectively were detected after electrophoresis,
indicating gene expression of pore components for at
least two channel types in this cell line. Furthermore, a
predicted band of 244 bp was found indicating the ex-
pression of SUR2B gene. The expression of SUR1 and
SUR2A genes was not detected (291 bp and 215 bp, re-
spectively). Altogether these results indicate that pore-
forming and regulatory subunits are expressed in this
Figure 1 Effect of Glibenclamide, a specific blocker of the KATP
channels, on cell growth. The figure shows the mRNA expression
of KATP channels components and the effect of Gli and minoxidil
(Min) on cell proliferation in MDA-MB-231 cells. Proliferation was
evaluated by counting of colonies with 50 cells or more and
expressed as percentage of values obtained with vehicle (means ±
SEM of three experiments on parallel). Panel A: mRNA expression of
KATP channels in MDA-MB-231 cells by RT-PCR analysis. Agarose gel
electrophoresis of PCR products showed bands corresponding to:
Kir6.1 (336 bp), Kir6.2 (301 bp), SUR2B (312 bp). No bands were
detected for SUR2A (215 bp) or SUR1 (291 bp). CN: negative control
Panel B: Inhibition of proliferation obtained with different
concentrations of Gli (10, 20, 30 or 50 μM). Insert shows the dose–
response curve used to determine IC50 (IC50 = 25 μM). Panel C:
Increase of proliferation obtained with Min 0.05; 0.5 or 5 μM. Panel
D: Results obtained with IC50 Gli plus different concentration of Min.
Panel B and C: *p < 0.05 vs. control; **p < 0.01 vs control; ***p <
0.001 vs. control, One way ANOVA and Dunnet post test. Panel D:
***p < 0.01 vs. Min 0.05 μM; vs. Min 0.5 μM; vs. Min 5 μM. ###p <
0.001 vs. Min 0.05 μM; vs. Min 0.5 μM; vs. Min 5 μM. One way
ANOVA and Tuckey post test.
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analyzed and Kir6.1, Kir6.2 and SUR1 were found
expressed in this cell line (data not shown).
Effect of glibenclamide on cell proliferation
The effect of Gli on cell proliferation was tested by
means of a clonogenic assay. A significant concentration
dependent inhibition on cell growth was observed when
Gli was added to cell cultures in concentrations over 10
μM; the IC50 value was 25.6 ± 3.2 μM (Figure 1B). The
increased doubling time (T value, Table 1) obtained in
the presence of 25 μM Gli is in concordance with the in-
hibition of proliferation previously demonstrated using
the clonogenic assay.
In order to support the hypothesis of KATP channels
involvement in MDA-MB-231 cell proliferation we used
minoxidil, a well known specific opener of these chan-
nels. The results showed an increase in cell clonogenic
growth for concentrations over 0.05 μM, which became
significant at 5 μM (Figure 1C). Figure 1D shows that
the increment in proliferation produced by the channel
opener was totally reversed by 25 μM Gli.
The analysis of cell cycle phase distribution demon-
strated that Gli produces a significant increase in the
number of cells in G1 phase at 24, 48 and 72 h post
treatment, clearly demonstrating a significant G0/G1 cell
cycle arrest (Figure 2A). A consequent decrease in cellsTable 1 Determination of cell doubling time
Treatment Duplication Time (hs)
Control 24.0 ± 4.3
Gli 34.6 ± 4.5 *
Gli: 25 μM gliblenclamide. * p < 0.05 vs control, t test.
Figure 2 (See legend on next page.)
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Figure 2 Effect of Glibenclamide on cell cycle progression. Panel A: Synchronized MDA-MB-231 cells were treated with IC50 Gli (25 μM) or
vehicle for 24, 48 or 72 h and the fraction of cells in each phase of cell cycle was evaluated by flow citometry. Gli treatment clearly arrested cells
at G0/G1 phase. Results are expressed as percentage of the value obtained with vehicle (means ± SEM of three experiments on parallel). °p < 0.01
vs control; *p < 0.001 vs control, t test. Left bars: control; right bars: Gli-treated cells. Panel B: A decrease in BrdU incorporation to DNA was
observed when cells were treated with 25 μM Gli for 48 h. Results are expressed as the means ± SEM of three experiments on parallel. *p < 0.05
vs. control, t test. Panel C: Expression of G1-S regulatory proteins in MDA-MB-231 cells treated with Gli or vehicle for 72 h was analyzed by
Western blot. Gli decreased the level of cyclin E and increased p27Kip1. Representative immunoblot images of cyclins D1, B1, E and p27Kip1 are
illustrated. Relative quantification was performed by densitometric analyses. Actin densitometric values were used to standardize for protein
loading. Bars represent the mean ± SEM of three independent experiments. **p < 0.01 vs control; ***p < 0.001 vs control, t test.
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Consistent with these observations, Gli inhibited the ac-
tive DNA synthesis when it was evaluated by BrdU in-
corporation (Figure 2B).
The expression of proteins implicated in the control of
different phases of the cell cycle was investigated by
Western blot analysis. Studies of proteins specifically
related with phase G1 of cell cycle demonstrated that 25
μM Gli reduced expression of cyclin E whereas cyclin
D1 remained unchanged after 72 h of treatment. Fur-
thermore, p27Kip1 levels were up-regulated in the same
experimental conditions. In addition, the level of cyclin
B1 expression, which is involved in the control of G2-M
transition, was not modified by Gli treatment.
Effect of glibenclamide on cell death
To determine if the decrease in proliferation exerted by
Gli could be due to an apoptotic effect, we assessed
apoptosis by two different methodologies. Results
showed that Gli did not increase the number of apoptotic
cells by Annexin-V staining (3.66 ± 0.62% in control vs
3.70 ± 0.69%) after 72 h of treatment (Figure 3). In ac-
cordance, neither it produced the disruption of theFigure 3 Evaluation of apoptosis by Annexin-V method. Apoptosis wa
positive control cells were treated with H2O2 (5 mM) for 30 minutes. Fluorescen
cytometry. Gli (25 μM) did not induce an increment in apoptosis of MDA-MB-2mitochondrial transmembrane potential (ΔΨm) that is
associated with mitochondrial dysfunction and linked to
cell death and loss of cell viability (Table 2).
It is known that the Bcl-2 family of mitochondrial pro-
teins is strongly linked to the process of apoptotic cell
death; some members of the family act as antiapoptotic
proteins such as Bcl-2, Bcl-xL, while others act as inductors
of cell death as Bcl-xS and Bax [24-26]. We determined the
expression of these proteins by flow cytometry and West-
ern blot. By both methodologies we showed that 72 h after
treatment with 25 μM Gli, the level of expression of pro-
apoptotic protein Bax was slightly increased in relation to
control at the same time, although this increase was not
statistically significant (Figure 4A and 4B). On the other
hand, antiapoptotic Bcl-2 protein did not modify its ex-
pression when cells were treated with Gli (Figure 4B). The
pro-apoptotic isoform, Bcl-xS, showed a very low expres-
sion while the antiapoptotic isoform Bcl-xL expression
levels were higher but did not significantly change with
Gli-treatment (Figure 4A).
We also evaluated the induction of cell senescence as
a mechanism of cell death. To identify the senescent
cells, senescence-associated β-galactosidase (SA-β-GAL)s assessed after incubating the cells with Gli or vehicle by 72 h. For
ce was evaluated immediately after Annexin-V staining by flow
31 cells. Positive Annexin-V cells are shown in both right quadrants.
Table 2 Effect of Gli on mitochondrial transmembrane
potential (ΔΨm)
Time (hs) ΔΨm (% of control)
24 99.7 ± 7.3
48 97.0 ± 3.9
72 94.3 ± 12.7
Gli: 25 μM glibenclamide. p:NS vs. control, One way ANOVA.
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25 μM Gli showed an increase in the percentage of sen-
escent cells versus those treated with vehicle (3.5 ± 0.4%
vs 1.2 ± 0.2%; Figure 5).Effect of glibenclamide on cell differentiation
Differentiation is one possible mechanism involved in
the loss of cell proliferative ability. In mammary cells
the accumulation of neutral lipids in cytoplasm is a
specific marker of this process. We evaluated by flow
cytometry the content of neutral lipids using Nile-red
staining and results demonstrated no differences be-
tween control and 25 μM Gli treated cells up to 7 days
(Table 3). Sodium butyrate, an effective differentiation
agent in ERα (+) and ERα (−) breast cancer cells [27],
was used as positive control.Cytostatic effect of glibenclamide
To determine whether the growth inhibitory effect
was reversible, a characteristic of cytostatic agents,
cells were treated with 25 μM Gli or vehicle for 3 or
7 days and then they were trypsinized and re-plated
at low density in the absence of any treatment to as-
sess clonogenic proliferation. Results in Figure 6
showed that there is no significant difference between
Gli-pretreated cells for different time periods and
control cells, suggesting that the antiproliferative ef-
fect of Gli is elicited only when the drug is present
and it does not involve cell toxicity.Combination treatments
We assayed the combination of Gli with tamoxifen or
doxorubicin to explore a possible increase in efficacy. The
growth of MDA-MB-231 cells was inhibited by tamoxifen
with an IC50 equal to 5 μM (Figure 7A). The concentration
of Gli that inhibited cell growth in a 50% (25 μM) was used
to evaluate the combined action of Gli plus tamoxifen. The
inhibitory effect exerted by the combination of Gli plus
tamoxifen was similar to that observed for Gli alone
(Figure 7B).
Doxorubicin also inhibited cell proliferation in a concen-
tration dependent manner (Figure 7C). The combination
of 25 μM Gli plus doxorubicin in doses over 0.05 nM wasmore effective to inhibit cell proliferation than single treat-
ments (Figure 7D).
Discussion
Different subtypes of potassium channels have been
shown to be directly implicated in normal and malignant
cell proliferation [9]. Some of these channels are overex-
pressed in tumors and therefore they are potential tar-
gets for anticancer therapies [28].
We have previously demonstrated that Gli exerts an
antitumoral action on NMU-induced mammary tumors
in rats, which is an experimental model similar in ER ex-
pression and hormone-dependence to human breast
cancer [29,30]. In these tumors Gli action was poten-
tiated by the combination with tamoxifen [31]. In this
paper we analyzed the effect of Gli in MDA-MB-231
ERα (−) breast cancer cell proliferation.
We studied the expression of mRNA for the different
subunits that constitute KATP channels in MDA-MB-231
cells and determined that these cells express both pore
forming subunits, Kir6.1 and Kir6.2, and the regulatory
subunit SUR2B. Coincidently, Bondestine et al. have re-
cently reported the expression of SUR2 protein in
MDA-MB-231cells, while SUR1 could not be detected in
this cell line [32]. In consequence two whole octameric
functional channels could be present in MDA-MB-231
cells. In specific tissues different subunit combinations
have been detected, e.g., pancreatic β cells and neurons
have Kir6.2/SUR1 channels, whereas skeletal muscle
expresses Kir6.2/SUR2A channels. These differences
imply that drugs may have distinct abilities to affect
KATP channels in diverse tissues depending on the type
of SUR expressed [20]. Gli binds to every type of SUR
and therefore inhibits the activity of all known KATP
channels [33]. When we assayed the effect of Gli on
MDA-MB-231 cell proliferation, results showed that Gli
inhibits clonogenic ability in a concentration-dependent
way, with an increment in population doubling time. It
has been reported that the potassium-dependent
changes in membrane potential play a crucial role in the
proliferation of many types of normal and tumor cells.
The opening of potassium channels in the cell mem-
brane produces a hyperpolarization of membrane poten-
tial which is required for the progression through the
cell cycle. As a consequence in the presence of potas-
sium channel blockers cell proliferation is inhibited
[34,35]. Woodfort et al. early determined that different
potassium channel antagonists, as Gli, produce a
concentration-dependent growth inhibition on MCF-7
cells with a significant arrest of cells in G0/G1 phase
[36]. Diverse drugs signaled as specific KATP channel
openers which include minoxidil, pinacidil and diaxozide
augment DNA synthesis and proliferation of normal and
tumor cells [37-39]. In the experiments using minoxidil
Figure 4 Expression of proteins involved in apoptosis. Panel A:
Bax and Bcl-xL/S expression determined by Western Blot employing
specific antibodies in MDA-MB-231 cells treated for 72 h with 25 μM
Gli (Gli) or vehicle (control) cells. The figure shows a representative
Western blot of three independent experiments and the
quantification of bands obtained for Bax and Bcl-xL/S protein. Bars
represent the mean ± SEM of three independent experiments. p:
Non significant (NS), t test. Panel B: Expression of Bcl-2 and Bax
protein in MDA-MB-231 cells treated by 72 h with 25 μM Gli (Gli) or
vehicle, obtained by flow cytometry. Bars represent the mean
fluorescence ± SEM obtained by three independent experiments.
p: NS, t test.
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eration in concentrations over 0.05 μM. In addition when
different concentrations of minoxidil were combined with
25 μM Gli the increment in proliferation was totally
reverted. Taken together, these results suggest that Gli
could reduce cell proliferation in MDA-MB-231 cells act-
ing through KATP channels.
The analysis of cell cycle progression indicated that
25 μM Gli produces an arrest in the G0/G1 phase of cell
cycle after 48 h of treatment. After release of serum starva-
tion, the diminution of the proportion of cells in S phase in
Gli treated cultures was confirmed by the decrease in BrdU
incorporation. The cell division cycle integrates several
processes and signal transduction pathways to commit the
progression of a cell through or its arrest in a specific cell
cycle phase. It is generally accepted that the cell cycle regu-
lators cyclin D1 and cyclin E play an important role in early
G1 and late G1 progression. In addition, the progression is
tightly regulated by the respective cyclin activated subunits
cyclin-dependent kinases (Cdks) and their inhibitors
(Cdkis). p27 is a member of the Kip/CIP family of Cdkis
known to act in the G1 phase of the cell cycle, preventing
G1-S transition [40,41]. The study of proteins involved in
the progression through the phases of cell cycle by immu-
noblot, has evidenced a decrease in cyclin E expression
with a raise in cyclin inhibitor p27Kip1 in Gli treated MDA-
MB-231 cells. It is known that the activity of cyclin E in
conjunction with its kinase subunit Cdk2, is limiting for
the passage of cells through the restriction point needed
for the progression of cells from G1 into S-phase [42].
p27Kip1 binds to the cyclinE/Cdk2 complex and inhibits
the kinase thus impeding G1-S passage [43]. Altogether
our results suggest that Gli inhibits MDA-MB-231 cell
proliferation by hindering G1-S transition. Other authors
have also reported that different potassium channels block-
ers and other agents that cause cell membrane
depolarization, produce the arrest of cells in G1 phase with
the involvement of different cyclins and inhibitors depend-
ing on the cell type [34]. Eto reported that various anti-
cancer agents specifically up-regulate p27Kip1 expression
without affecting expression of the other regulatory pro-
teins of G1-S cell cycle transition in human breast cancer
Figure 5 Evaluation of Senescence. MDA-MB-231 cells were
cultured for 48 h with 25 μM Gli or with vehicle. Senescence was
assessed by the activity of SA-β-GAL. Panel A: representative
photographs where positive SA-β-GAL cells are indicated by arrows.
Gli produces an increment in cell senescence. Panel B: Percentage of
cells SA-β-GAL positive were calculated by counting of at least 1000
cells (630X). Bars represent the mean ± SEM of three independent
experiments. *p < 0.001 vs. control, t test.
Figure 6 Evaluation of cytotoxic or cytostatic effect. MDA-MB-231
cells treated with 25 μM Gli or vehicle for 3 or 7 days were re-seeded at
low density to evaluate clonogenic capacity. After 10 days in culture, the
number of colonies was determined and normalized to the number of
colonies in controls. Bars show that Gli pre-treatment did not
signifcantly affect clonogenic capacity. p: NS, One way ANOVA.
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reported that the up-regulation of p27Kip1 expression in
these cell lines by anti-cancer agents linearly and positively
correlates with the degree of growth inhibition of NMU-
induced mammary tumors by the same anti-cancer agent
[44].
It has been suggested that chemotherapeutic agents
can prevent mammary carcinogenesis and tumor growth
through different mechanisms that include apoptosis,
differentiation and senescence. Regardless of the mech-
anism, the evaluation of new antitumoral drugs has as a
goal to stop the cell proliferation and produce the death
of the tumor cell by apoptotic or non-apoptotic means
[45]. Previously, working with NMU-induced mammaryTable 3 Effect of Gli on neutral lipid accumulation
Time (days) Mean Fluorescence of Nile Red (% of control)
Gli Na Butyrate
2 92.3 ± 4.7 134.3 ± 6.7 ***
3 99.3 ± 1.7 165.7 ± 7.3 ***
7 99.0 ± 10.1 192.7 ± 5.3 ***
Gli: 25 μM glibenclamide. Na Butyrate: 10 mM Sodium butyrate as the positive
control. p: NS Gli vs control; *** p < 0.001 butyrate vs control, One way ANOVA
and Dunnet test.tumors in rats, we reported that Gli clearly produced the
inhibition of tumor growth through a decrease in cell
proliferation and an increase in cell apoptosis and differ-
entiation [31]. It has been reported that Gli produces
apoptosis in malignant cell lines such as hepatoblastoma
and gastric cancer cells [6,7]. Furthermore, Iwakura and
coworkers found that Gli produces a sustained increase
in the entrance of Ca2+ to the cells inducing their death
through apoptosis [46]. On the contrary, we demon-
strated that Gli neither produced apoptosis nor triggered
the early events of this mechanism of cell death in
MDA-MB-231 cells. We also studied the expression of
apoptosis related proteins and determined that Gli did not
significantly affect the ratio of the expression of Bax/Bcl-2
proteins at any time evaluated. The relation between antia-
poptotic and apoptotic proteins of Bcl-2 family is a better
determinant of the susceptibility to apoptosis than the ex-
pression of each member separately.
In view that some chemotherapeutic agents are able to
produce cell senescence as part of their mechanism of
action [45], this possible way of action was studied in
the MDA-MB-231 cells treated with Gli. Data obtained
in our experiments indicate that there is a slight increase
in cell senescence after Gli treatment. However, Gli did
not result cytotoxic for neoplastic MDA-MB-231 cells so
they clearly keep their clonogenic capacity after being
exposed to Gli for seven days. Our results are in agreement
with the reported by Woodfork et al., showing that Gli
induced a cell cycle arrest in G0/G1 phase in MCF-7 cells
that could be reverted by the removal of the drug [36].
Mammary tumor cell differentiation is characterized by
an arrest in cell proliferation, nuclear and cytoplasmatic
Figure 7 Glibenclamide combination with antineoplasic drugs. MDA-MB-231 cell proliferation was evaluated by counting of colonies with 50
cells or more and expressed as percentage of controls (means ± SEM of three independent experiments). Panel A: Results obtained with
tamoxifen (Tam) 0.1, 0.5, 1 or 5 μM. Panel C: Inhibition of proliferation obtained with doxorubicin (Dox) 0.01, 0.05, 0.1 or 0.5 nM. Panel B and D:
Results obtained for combination of 25 μM Gli plus different concentrations of Tam or Dox. Panel A and C: *p < 0.05 vs. control; **p < 0.01 vs.
control; ***p < 0.001 vs. control, ANOVA and Dunnet post test. Panel B: p: NS vs. Gli 25 μM, t test. Panel D: *p < 0.05 vs. Dox 0.01 nM, vs. Dox 0.1 nM;
**p < 0.001 vs Dox 0.05 nM; +p < 0.05 vs. Dox 0.05 nM + Gli 25 μM; ++p < 0.001 vs. Dox 0.1 nM + Gli 25 μM. One way ANOVA and Tuckey post test.
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sion of the components of milk such as lipids [47,48]. The
accumulation of neutral lipid drops in the cell cytoplasm is
used as a marker of this process. In our research Gli did
not induce differentiation in MDA-MB-231 cells after
treatment for seven days.
Antiestrogens such as tamoxifen are widely used for
the treatment of ERα (+) breast cancer. Nevertheless,
tamoxifen may elicit pro-apoptotic effects in ERα (−)
breast cancer cells by the modulation of various cell sig-
naling pathways in an ER-independent manner [49-53].
However, these effects have generally been reported when
relatively high concentrations of tamoxifen were used. In
the present work we used tamoxifen in combination with
Gli as a strategy to enhance its action in ERα (−) breast
cancer even if Gli acts as cytostatic in MDA-MB-231 cells.
In our experiments tamoxifen inhibited proliferation sig-
nificantly at quite high concentrations (5 μM) as expected
and the combination treatment did not produce a higher
inhibitory effect on cell proliferation than each treatment
alone. Abdul et al. demonstrated that two nonspecificpotassium channels blockers, amiodarone and dequali-
nium, potentiated the growth inhibitory effects of tamoxi-
fen on human breast, prostate and colon cancer cell lines
[38]. In view of our previous results in NMU-induced
mammary tumors [31] it could be suggested that Gli may
potentiate tamoxifen action only in breast hormone-
dependent cells.
Doxorubicin is extensively used in chemotherapy for
patients with metastatic breast cancer. In spite of its ex-
cellent anti-tumor activity, the associated acute and
chronic toxicities lead to a relatively low therapeutic
index [54]. Therefore, combination treatment with a
non-toxic drug which can lower the dose would be ad-
vantageous. Our results indicate that the combined
treatment of Gli and doxorubicin displayed an additive
anti-proliferative effect. In this regard, Gli was found to
inhibit multidrug resistance protein (MRP1) activity in
human lung cancer cells [55]. In addition it has been also
demonstrated that the overexpression of the inwardly
rectifying K channel Kir2.2 decreased doxorubicin-
induced reactive oxygen species accumulation and cell
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ther studies are to needed to fully investigate the
mechanism involved in the antiproliferative response of
MDA-MB-231 cells to the combined treatment gliben-
clamide with doxorubicin.
Conclusions
Gli, a drug widely used in clinics for the treatment of type
2-diabetes, is atoxic at doses routinely employed and of
low cost. Our experimental data clearly demonstrated that
it produces a cytostatic effect in MDA-MB-231 cells inhi-
biting the G1-S phase progression without inducing cell
death or differentiation. Nevertheless, in spite of the lack of
cytotoxic action, the interesting observation about the ef-
fect of the combination of Gli with doxorubicin on prolif-
eration warrants an exhaustive research to elucidate the
pathways involved in this interaction, leading to the con-
sideration of a novel role for Gli as an adjuvant in breast
cancer treatment.
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